Should I buy or sell Vaxxinity stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VAXX shares. View VAXX analyst ratings or view top-rated stocks .

What is Vaxxinity's stock price target for 2024?

1 brokerages have issued 12 month price targets for Vaxxinity's stock. Their VAXX share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 900.0% from the stock's current price. View analysts price targets for VAXX or view top-rated stocks among Wall Street analysts .

How have VAXX shares performed in 2024?

Vaxxinity's stock was trading at $0.85 on January 1st, 2024. Since then, VAXX shares have decreased by 17.6% and is now trading at $0.70. View the best growth stocks for 2024 here .

When is Vaxxinity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024. View our VAXX earnings forecast .

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) announced its quarterly earnings data on Monday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16).

What ETF holds Vaxxinity's stock ?

Amplify Treatments, Testing and Advancements ETF holds 35,725 shares of VAXX stock, representing 0.58% of its portfolio.

When did Vaxxinity IPO?

(VAXX) raised $90 million in an initial public offering (IPO) on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share.

Who are Vaxxinity's major shareholders?

Vaxxinity's stock is owned by a variety of institutional and retail investors. Top institutional investors include Ieq Capital LLC (0.07%). Insiders that own company stock include Lou Reese, Mei Mei Hu, Movers Lab Fund I Lp Prime and United Biomedical Inc. View institutional ownership trends .

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VAXX

Vaxxinity (VAXX) Stock Price, News & Analysis

$0.70

0.00 (0.00%)

(As of 02/9/2024 08:57 PM ET)

Compare

Today's Range: $0.68
▼
$0.72
50-Day Range: $0.67
▼
$1.03
52-Week Range: $0.63
▼
$3.26

Volume: 109,500 shs
Average Volume: 179,068 shs
Market Capitalization: $88.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $7.00

Get Vaxxinity alerts:

Vaxxinity MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 900.0% Upside
$7.00 Price Target
Short Interest: Bearish
9.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.23
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.51) to ($0.42) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.84 out of 5 stars

Medical Sector

655th out of 922 stocks

Pharmaceutical Preparations Industry

312th out of 428 stocks

3.5

Analyst's Opinion

Consensus Rating
Vaxxinity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Vaxxinity has a forecasted upside of 900.0% from its current price of $0.70.
Amount of Analyst Coverage
Vaxxinity has received no research coverage in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
9.69% of the float of Vaxxinity has been sold short.
Short Interest Ratio / Days to Cover
Vaxxinity has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Vaxxinity has recently increased by 3.88%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Vaxxinity does not currently pay a dividend.
Dividend Growth
Vaxxinity does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VAXX.

4.0

News and Social Media Coverage

News Sentiment
Vaxxinity has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Vaxxinity this week, compared to 0 articles on an average week.
Search Interest
8 people have searched for VAXX on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.
MarketBeat Follows
4 people have added Vaxxinity to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaxxinity insiders have not sold or bought any company stock.
Percentage Held by Insiders
59.07% of the stock of Vaxxinity is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 9.26% of the stock of Vaxxinity is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Vaxxinity are expected to grow in the coming year, from ($0.51) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vaxxinity is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaxxinity is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaxxinity has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vaxxinity Stock (NASDAQ:VAXX)

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.

VAXX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VAXX Stock News Headlines

January 30, 2024 | finance.yahoo.com

Vaxxinity, UF Join Forces Against Neurodegenerative Diseases

January 30, 2024 | finance.yahoo.com

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

February 12, 2024 | Behind the Markets (Ad)

"Chilling War Games Show US Forces Crushed" – FOX NEWS

=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>

January 19, 2024 | finance.yahoo.com

Vaxxinity & UCF to Collaborate on Space Medicine Research

January 18, 2024 | finance.yahoo.com

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

January 3, 2024 | finance.yahoo.com

Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference

December 12, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights Biogen, Prothena, AC Immune's and Vaxxinity

November 21, 2023 | markets.businessinsider.com

Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others

February 12, 2024 | The Oxford Club (Ad)

PROOF: New One Ticker (Weekly) Payouts

A multimillionaire stock trader's research explains how focusing on just one ticker every week has generated payouts up to a rare 2,614% in under 11 days...AND he's brought proof to show the world!

November 20, 2023 | foxnews.com

Several Alzheimer's vaccines enter clinical trials amid breakthrough treatments' success

November 20, 2023 | msn.com

Researchers return to Alzheimer's vaccines, buoyed by recent drug success

November 13, 2023 | finance.yahoo.com

Vaxxinity to Present at Upcoming November Medical and Investor Conferences

November 8, 2023 | finance.yahoo.com

Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 10, 2023 | finance.yahoo.com

Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline

September 7, 2023 | finance.yahoo.com

Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)

August 11, 2023 | finance.yahoo.com

Vaxxinity Says UB-311 Shows Potential Advancements in Alzheimer’s Treatment

August 10, 2023 | finance.yahoo.com

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

August 9, 2023 | finance.yahoo.com

Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 28, 2023 | finance.yahoo.com

Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director

July 28, 2023 | finance.yahoo.com

Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director

July 17, 2023 | finance.yahoo.com

Promising Milestone in Neurodegenerative Disease Treatment: Vaxxinity’s UB-312 in Parkinson’s Patients

July 17, 2023 | finance.yahoo.com

Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients

June 22, 2023 | finance.yahoo.com

Positive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s Disease

June 22, 2023 | finance.yahoo.com

Vaxxinity Touts Encouraging Data From Early-Stage Parkinson's Vaccine Trial

June 22, 2023 | finance.yahoo.com

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease

May 9, 2023 | finance.yahoo.com

Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 3, 2023 | finance.yahoo.com

Vaxxinity, Inc.'s (NASDAQ:VAXX) biggest owners are private companies who got richer after stock soared 23% last week

See More Headlines

Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/27/2023
Today: 2/11/2024
Next Earnings (Estimated): 3/25/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VAXX
CUSIP: N/A
CIK: 1851657
Web: www.vaxxinity.com
Phone: 254-244-5739
Fax: N/A
Employees: 87
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $7.00
High Stock Price Target: $7.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +900.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-75,220,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -158.06%
Return on Assets: -82.30%

Debt

Debt-to-Equity Ratio: 0.51
Current Ratio: 2.15
Quick Ratio: 2.15

Sales & Book Value

Annual Sales: $70,000.00
Price / Sales: 1,267.50
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.49 per share
Price / Book: 1.43

Miscellaneous

Outstanding Shares: 126,750,000
Free Float: 51,877,000
Market Cap: $88.73 million
Optionable: Not Optionable
Beta: 2.40

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Louis Garfield Reese IV (Age 42)
Co-Founder & Executive Chairman of the Board
Comp: $83.28k
Ms. Mei Mei Hu J.D. (Age 41)
CEO & Director
Comp: $551.73k
Dr. Peter Powchik M.D. (Age 67)
Executive VP, Global Scientific Director and Director
Mr. Jason Pesile CPA (Age 51)
M.B.A., Senior Vice President of Finance & Accounting
Ms. Sumita Ray J.D. (Age 50)
Chief Legal & Administrative Officer
Mr. Jon Harrison
Chief Government Officer
Mr. Mark Joinnides MSE
Chief of Staff
Ms. Amy B. Fix M.B.A.
M.S., R.A.C., Chief Regulatory Officer
Dr. Jean-Cosme Dodart Ph.D.
Senior Vice President of Research
Mr. Dario Mirski M.D.
Senior Vice President of Neuro / Chronic Diseases

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VAXX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxxinity stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VAXX shares.
View VAXX analyst ratings or view top-rated stocks.
What is Vaxxinity's stock price target for 2024?: 1 brokerages have issued 12 month price targets for Vaxxinity's stock. Their VAXX share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next year. This suggests a possible upside of 900.0% from the stock's current price.
View analysts price targets for VAXX or view top-rated stocks among Wall Street analysts.
How have VAXX shares performed in 2024?: Vaxxinity's stock was trading at $0.85 on January 1st, 2024. Since then, VAXX shares have decreased by 17.6% and is now trading at $0.70.
View the best growth stocks for 2024 here.
When is Vaxxinity's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 25th 2024.
View our VAXX earnings forecast.
How were Vaxxinity's earnings last quarter?: Vaxxinity, Inc. (NASDAQ:VAXX) announced its quarterly earnings data on Monday, March, 27th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.16).

What ETF holds Vaxxinity's stock ?: Amplify Treatments, Testing and Advancements ETF holds 35,725 shares of VAXX stock, representing 0.58% of its portfolio.
When did Vaxxinity IPO?: (VAXX) raised $90 million in an initial public offering (IPO) on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share.
Who are Vaxxinity's major shareholders?: Vaxxinity's stock is owned by a variety of institutional and retail investors. Top institutional investors include Ieq Capital LLC (0.07%). Insiders that own company stock include Lou Reese, Mei Mei Hu, Movers Lab Fund I Lp Prime and United Biomedical Inc.
View institutional ownership trends.
How do I buy shares of Vaxxinity?: Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VAXX) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vaxxinity (VAXX) Stock Price, News & Analysis

Vaxxinity MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vaxxinity Stock (NASDAQ:VAXX)

VAXX Stock Price History

VAXX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VAXX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™